QSimulate is a Boston-based quantum simulation technology company developing physics-powered solutions to accelerate drug discovery, improve molecular modeling, and reduce research and development timelines, with additional offices in Ghent and Tokyo. Pulse 2.0 interviewed QSimulate Co-Founder and CEO Toru Shiozaki to learn more about his scientific background, the company’s quantum simulation technology, pharmaceutical industry partnerships, $11 million in funding, and plans to expand applications across drug discovery, advanced materials, and life sciences.
Toru Shiozaki’s Background
When asked about his professional background and how his academic research influenced his entrepreneurial journey, Shiozaki shared:
I am a scientist by training, and served as a chemistry professor at Northwestern University before partnering with Caltech professor Garnet Chan in 2018 to launch QSimulate. It was during my time in academia that I saw that quantum mechanics can help uncover insights about the interactions between drug molecules and protein targets, helping accelerate drug discovery.
We launched QSimulate to bring frontier quantum simulation technologies directly from the lab to the market to accelerate drug discovery and industrial innovation.
How The Idea For QSimulate Came Together
Reflecting on the origins of QSimulate and the challenges of traditional molecular simulation, Shiozaki recalled:
Human biology is complex and simulating interactions between drugs and proteins at the molecular level has long been a notoriously difficult challenge, especially with conventional AI methods.
After years in scientific simulation research, I wanted to translate R&D into tangible, real-world impact. I saw that quantum mechanics was often the missing ingredient in drug discovery and started QSimulate to fill that gap.
QSimulate is flipping the script with a quantum physics-first approach, making drug discovery faster and more accurate by directly modeling molecular behavior based on the ground truth of the microscopic world.
Favorite Memory Working At QSimulate
Discussing his favorite memory working at the company, Shiozaki highlighted the breakthrough that made its quantum simulation technology commercially practical:
My favorite memory so far is successfully unlocking the “lab to market” impact of our technology, seeing our platform reduce complex simulations from months to mere hours for our customers and partners.
For a long time, the field agreed that quantum mechanics was the right way to model how drug molecules interact with proteins but the computing cost and wait times made it impractical. There were no commercial offerings for pharmaceutical companies because quantum-powered simulations were complex and compute intensive.
The breakthrough came when we launched the QSimulate quantum mechanics engine, which performs predictive molecular simulations 1,000 times faster than traditional methods.
Challenges In Commercializing Quantum Simulation Technology
When asked about challenges QSimulate has encountered and how the company addressed them, Shiozaki described the role of scientific feedback in developing its QUELO platform:
QUELO, now one of the most successful solutions in our portfolio, was born out of early challenges. When we first previewed QUELO, users were initially skeptical. Our core users are scientists, who are trained to question everything.
We leaned in on that critique. Their feedback made them our toughest product testers, and we spent an extra two years using their rigorous input to iterate.
While scientists are a tough crowd to win over, their feedback ultimately helped make QUELO one of our most widely used tools today.
Core Products And Features
When asked about QSimulate’s core products and capabilities, Shiozaki identified the company’s quantum simulation portfolio:
QSimulate’s portfolio of quantum solutions includes QUELO, QIDO, QuantumFP, QuValent and more.
How QSimulate’s Technology Has Evolved
Looking back at the company’s technological evolution since launching, Shiozaki outlined the development of its quantum simulation engine and expanding portfolio of specialized applications:
When we launched our breakthrough quantum engine in 2024, we became the first to enable real-time quantum simulations directly within the drug discovery pipeline.
Since then, we have focused on evolving this core engine to power an ever-expanding portfolio of specialized solutions.
Today, our portfolio includes QUELO, a quantum-powered simulation platform featuring enhanced sampling techniques designed to handle larger molecules and peptide drugs.
We also added QIDO, a quantum-integrated chemistry platform built to accelerate “molecule-to-market” timelines for both drug and materials discovery.
Our portfolio also includes the industry’s first quantum-powered solutions for the lead optimization of covalent drug molecules and those interacting with metal ions, which are critical for targeting cancer therapies and complex diseases like HIV and Alzheimer’s.
Significant Company Milestones And Customer Success Stories
Highlighting QSimulate’s partnerships with global technology, pharmaceutical, and industrial companies, Shiozaki detailed the company’s progress and feedback from collaborators:
We collaborate with global leaders including Mitsui, JT Pharma, five of the top 20 pharmaceutical companies, and Google, whose joint work with us on the “Quantum Echoes” algorithm was featured in the journal Nature.
Across the industry, our partners are already seeing the impact of our platform.
JSR Corporation says QSimulate “offers a path to an early quantum advantage.” Panasonic Holdings Corporation says QSimulate is “expected to offer opportunities for early-stage validation in preparation for future breakthroughs.”
Chugai Pharmaceutical emphasizes that our technology is “making reaction pathway exploration easier and more efficient than ever,” ultimately driving innovation in drug discovery and the advancement of pharmaceutical development.
Funding And Revenue Metrics
When asked about QSimulate’s funding and financial performance, Shiozaki disclosed:
To date, we have raised $11 million while building strategic collaborations with global leaders like Mitsui, Google, and five of the world’s top 20 pharmaceutical companies.
Quantum computing is often seen as extremely cost-prohibitive, but QSimulate is already revenue healthy.
AI companies often require “mega rounds” of financing to acquire and train on massive datasets. In contrast, physics-based quantum simulation companies like QSimulate require what we call “mega science” but less to scale.
QSimulate’s scientific foundation serves as a powerful technical moat and a significant barrier to entry for others.
Total Addressable Market
Addressing the total addressable market QSimulate is pursuing, Shiozaki identified opportunities across several major industries:
Our total addressable market lies at the intersection of the pharmaceutical, energy, and chemical sectors.
By shortening critical “molecule-to-market” timelines, QSimulate is positioned to bring immense value across all three of these global industries.
What Differentiates QSimulate From Its Competition
When asked what distinguishes QSimulate from competing AI-driven drug discovery and molecular simulation platforms, Shiozaki emphasized the company’s physics-first technology and scientific foundation:
AI companies often require “mega rounds” of financing to acquire and train on massive datasets. In contrast, physics-based quantum simulation companies like QSimulate require what we call “mega science” but less to scale.
QSimulate’s scientific foundation serves as a powerful technical moat and a significant barrier to entry for others.
Through our quantum physics-first approach, we have pioneered quantum chemistry reformulations to simulate complex drug-protein interactions at a subatomic level with high precision and 1,000x faster than conventional methods.
Future Company Goals
Outlining QSimulate’s future priorities, Shiozaki discussed plans to expand its quantum simulation capabilities, grow its team, and deepen partnerships with global organizations:
QSimulate will continue adding new quantum solutions to our portfolio to accelerate innovation in drug discovery, advanced materials, and the life sciences.
We are currently hiring, scaling operations, and expanding our platform to meet the demand of our collaborations with multinational companies, including Google, Mitsui, JT Pharma, and five of the world’s top 20 pharmaceutical companies.
The Future Of Quantum Technology And AI In Drug Discovery
Sharing additional perspectives on the relationship between artificial intelligence and quantum simulation, Shiozaki emphasized their complementary roles in advancing drug discovery:
Has AI in drug discovery hit a wall? That’s a common media headline, but we see it differently.
QSimulate has pioneered a quantum mechanics approach to unlock molecular insights in drug discovery that conventional AI methods cannot reach.
But, as AI continues to evolve, quantum mechanics will be more important than ever in the next frontier of drug discovery where both quantum and AI technologies will act as complementary forces.
